LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial

BACKGROUND: Cachexia is a formidable clinical challenge in pancreatic cancer. We assessed LY2495655 (antimyostatin antibody) plus standard‐of‐care chemotherapy in pancreatic cancer using cachexia status as a stratifier. METHODS: In this randomized, phase 2 trial, patients with stage II–IV pancreatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Golan, Talia, Geva, Ravit, Richards, Donald, Madhusudan, Srinivasan, Lin, Boris Kin, Wang, Haofei Tiffany, Walgren, Richard A., Stemmer, Salomon M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204586/
https://www.ncbi.nlm.nih.gov/pubmed/30051975
http://dx.doi.org/10.1002/jcsm.12331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204586/
https://www.ncbi.nlm.nih.gov/pubmed/30051975
http://dx.doi.org/10.1002/jcsm.12331

Ejemplares similares